ORIGINAL RESEARCH ARTICLE

Histopathological characteristics of lateral lymph nodes dictate local or distant metastasis and prognosis in low rectal cancer patients

Takeshi Suto, Toshihiko Sato and Hazime Iizawa

Department of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan

Abstract:
Objectives: The therapeutic value of lateral lymph node dissection in low rectal cancer (RC) patients remains a matter of debate. The present study evaluated the dissection value of each lateral lymph node, based on its histopathological characteristics. Methods: This study enrolled 381 consecutive RC patients with bilateral lateral lymph node dissection, from 1995 to 2014. We investigated their clinicopathological characteristics, and the therapeutic value of each lymph node dissection. The therapeutic values of the distal internal iliac and obturator lymph nodes were further investigated on the basis of histopathological classifications, as follows: minimum metastasis (Type A), massive metastasis (Type B) without capsular invasion, and invasive metastasis (Type C) with capsular invasion and were evaluated by the local or distant recurrence and 5 year overall survival. Results: Among the lateral lymph nodes, the therapeutic values of distal internal iliac (6.1) and obturator (7.4) lymph node dissection were higher than those of common (0.4) and proximal iliac (1.2) lymph node dissection. However, our further investigation revealed that the 5 year overall survival rates of Type C (obturator/distal iliac) were 12.5%/22.9%, whereas those of Type A and Type B were 100%/91.6% and 77.8%/50.0%, respectively. Conclusions: Metastasis and prognosis of RC patients depend on the histopathological characteristics of the distal internal iliac and obturator lymph nodes. The present study provides new insights for choices of appropriate treatments for RC patients.

Keywords:
rectal cancer, lateral lymph node dissection, chemoradiotherapy, therapeutic value, histopathological characteristic

Introduction

The indication or concept of lateral lymph node dissection for rectal cancer (RC) patients is still under debate. Previous studies reported that the prevalence of lateral lymph node metastasis was 13.9% to 25.5% in RC patients treated with lateral lymph node dissection. Several studies in Japan revealed that the 5 year overall survival rate was 37.9% to 49% in RC patients with lateral lymph node metastasis. Lateral lymph node metastasis is a risk factor of local recurrences in RC patients. A Japanese study reported that more than 80% of RC patients with lateral lymph node metastasis involved the internal iliac, internal pudendal, and obturator lymph nodes.

Total mesorectal excision for RC, which was proposed by Heald et al., is a surgical procedure to control the local recurrence. The Japanese Clinical Oncology Group (JCOG) study revealed that the noninferiority of mesorectal excision with lateral lymph node dissection was not confirmed in the intent-to-treat analysis and that total mesorectal excision with lateral lymph node dissection had a lower prevalence, compared with total mesorectal excision alone. The Japanese Society for Cancer of the Colon and Rectum guidelines recommend total mesorectal excision with lateral...
lymph node dissection as the gold standard procedure for RC patients. In Western countries, based on the Guideline 2000 for colon and RC surgery, lateral lymph node metastasis is a metastatic disease that requires chemoradiotherapy, and thus, preventative lateral lymph node dissection is not indicated for every RC patient but for patients with suspected lateral lymph node metastasis before preoperative diagnosis. The treatment strategy or different concept for lateral lymph nodes may affect the local recurrence and prognosis of RC patients. Recent reports suggested that lateral lymph node dissection decreased the local recurrence and had prognostic benefits. However, even in RC patients with lateral lymph node metastasis, some patients had a good prognosis and others had a poorer one. The underlying cause of this difference remains unknown.

In the present study, we evaluated the therapeutic value of each lateral lymph node dissection. Next, we classified the dissected metastatic internal iliac and obturator lymph nodes into three types, as follows: minimum, massive, and invasive metastasis types, by their histopathological characteristics. Finally, we investigated the dissection effects of the three representative types of lymph nodes on the local or distant recurrence and the 5 year survival of RC.

Methods

Rectal cancer patients and lateral lymph node dissection

The study included patients who were diagnosed with advanced lower RC and underwent radical surgery with bilateral lateral lymph node dissection at the Yamagata Prefectural Central Hospital, from January 1995 to December 2014. Inclusion criteria were as follows: histologically confirmed RC and lymph node metastasis and no preoperative chemoradiotherapy. The lateral lymph node dissection is indicated for clinical stages T3 and T4 lower RC patients, according to the clinical guidelines for colorectal cancer. Lower RC is defined as existing between the peritoneal reflection and the upper border of the anal canal and includes tumors with lower borders located caudal to the peritoneal reflection. The histological type and the clinical stage of RC patients were defined according to the tumor node metastasis classification system. Clinicopathological and laboratory information was available at our hospital database. After surgery, the RC patients were initially followed every 3 months for 3 years and consequently followed every 6 months for 2 years. A whole-body computed tomography scan or abdominal echogram was performed every 6 months for 5 years.

Definition of lateral lymph nodes

The dissection of lateral lymph nodes was set to the common iliac lymph node region (273), proximal internal iliac lymph node region (263P), distal internal iliac lymph node region (263D), and obturator lymph node region (283).

Figure 1. Schematic image showing the locations of the right lateral lymph nodes. The common iliac lymph node region (273), proximal internal iliac lymph node region (263P), distal internal iliac lymph node region (263D), and obturator lymph node region (283).

Evaluation of the effect of lateral lymph node dissection on 5 year overall survival rates

The effect of lateral lymph node dissection was estimated by the therapeutic value, by multiplying the frequency of lymph node metastasis (A; %) and the 5 year survival rate (B; %) of RC patients with lateral lymph node metastasis. The therapeutic value was calculated as $A \times B/100$. When both lymph nodes were positive for metastasis, they were individually counted and evaluated. In the operative procedure, the central lymph nodes around 253 were initially dissected, and subsequently the lateral lymph nodes were dissected. The lymph nodes and their surrounding adipose and connective tissues were totally dissected.

Histopathological classification of metastatic lateral lymph nodes and the dissection effect on local or distant metastasis and 5 year overall survival

The metastatic internal distal iliac (263D) and obturator lymph...
(283) lymph nodes were classified into three types by their histopathological characteristics, as follows: minimum metastasis (Type A), marginal sinus metastatic lesions; massive metastasis (Type B), without capsular invasion; and invasive metastasis (Type C), with capsular invasion and not tumor nodules. These are not cancer nodules (Figure 2). Dissected lymph nodes were fixed in 10% buffered-formalin solution for about 48 h. After fixation, the characteristics of the lymph nodes were judged by hematoxylin-eosin staining of the maximum cut surface and classified into the three types. The dissection benefits of the three types of lymph nodes were individually estimated by local or distant recurrence and 5 year overall survival.

**Statistical analysis**

All statistical analyses were performed using the statistical analysis software, JMP, Version 11 (SAS Institute Inc., Cary, NC). The survival rate was calculated by employing the Kaplan-Meier method, and the log-rank test was used to compare the overall survival between the two groups. Differences between groups were considered significant at value of $p < 0.05$.

**Results**

**Clinicopathological characteristics and operation types of RC patients with lateral lymph node dissection**

In total, 544 RC patients were enrolled. The eligible study population comprised 381 RC patients with lateral lymph node dissection (Table 1). The clinicopathological characteristics and operation types of the RC patients are shown in Table 1. There were about twice as many male RC patients (258) than female ones (123). Most histologic types of RC comprised well (tub1)- and moderately (tub2)-differentiated types. The lateral lymph node metastasis was detected in 64 RC patients (16.8%). The median duration of follow-up was 61.5 months (range: 28 to 228 months). Most RC operation types comprised low anterior resection and abdominal perineal resection. Figure 3 showed the cumulative 5 year overall survival rates in RC patients with (56.5%) or without (76.6%) lateral lymph node metastasis. The lateral lymph node metastasis decreased the 5 year overall survival of RC patients.

**Therapeutic value of lateral lymph node dissection**

The therapeutic value of each lymph node dissection is
Table 1. Clinicopathological Characteristics of Our RC Patient Cohort (381).

| Parameters                          | Number     |
|-------------------------------------|------------|
| Age (years) [median (range)]        | 66 (31-86) |
| Gender                              |            |
| Male                                | 258 (67.7) |
| Female                              | 123 (32.3) |
| Tumor size: median (range) (cm)     | 5.0 (0.9-17.0) |
| Histological type                   |            |
| tub1                                | 189 (49.6) |
| tub2                                | 164 (43.0) |
| por, muc                            | 28 (7.4)   |
| Pathological lateral lymph node metastasis |        |
| Yes                                 | 64 (16.8)  |
| No                                  | 317 (83.2) |
| pStage                              |            |
| I                                   | 74 (19.4)  |
| II                                  | 114 (29.9) |
| III                                 | 177 (46.5) |
| IV                                  | 16 (4.2)   |
| Type of operation                   |            |
| Low anterior resection              | 209 (54.8) |
| Inter sphincteric resection         | 40 (10.5)  |
| Abdomino perineal resection         | 123 (32.3) |
| Total pelvic exenteration           | 6 (1.6)    |
| Hartmann                            | 3 (0.8)    |

shown in Table 2. The prevalence of lymph node metastasis was higher in the 251-1-T and 251-1-O lymph nodes than the 251-2-A and 253 lymph nodes. The metastatic prevalence of the 251-1-A lymph node was low, and its 5 year survival rate was low. The therapeutic values of the 251-1-T and 251-1-O lymph nodes were also higher than those of the 251-2-A and 253 lymph nodes. The prevalence of the 263D and 283 lymph nodes was 9.7% and 11.5%, respectively, but their 5 year survival rates were higher than 252 and 253, and those of the other lateral lymph nodes. These results relatively increased their therapeutic values.

Three types of 263D and 283 lymph nodes revealed different effects on local or distant metastasis and 5 year over survival

The effects of metastasis and the 5 year overall survival for the three types of 263D and 283 lymph nodes are shown in Table 3 and Figure 4. Among the 283 lymph nodes (44 in total), there were 20 Type C (invasive metastasis; local/distant, 7/16; and 5 year survival, 22.9%), 18 Type B (massive metastasis; 1/5 and 77.8%), and 6 Type A (minimal metastasis; 0/1 and 100%). For the 263D lymph nodes (34 total), there were 16 Type C (local/distant; 6/14 and 5 year survival; 12.5%), 6 Type B (2/3 and 50.0%), and 12 Type A (0/1 and 91.6%). For both lymph nodes, Type A revealed few local or distant metastases, and a prominent 5 year overall survival, whereas Type C increased the prevalence of local and distant metastases, including the liver, lung, and paraaortic lymph nodes, and reflected a poor 5 year overall survival. Expectedly, for both lymph nodes, Type B exhibited the intermediate prevalence of local and distant metastases and a 5 year overall survival between those of Type A and Type C. These findings indicated that the histopathological characteristics of the 263D and 283 lymph nodes dictated the local or distant metastasis and the prognosis.

Discussion

In the present study, the prevalence of lateral lymph node metastasis and its 5 year overall survival rate in RC patients were 16.8% and 56.5%, respectively. Both findings are compatible with those of previous reports. The therapeutic values of lateral lymph node dissection were evaluated. The therapeutic values of the internal iliac (263D) and obturator (283) lymph nodes were higher, as compared with those of the 263P, 273, 252, and 253 lymph nodes. Thus, the dissection of the 263D and 283 lymph nodes was effective, whereas the dissection of the 263P and 273 lymph nodes revealed no advantages. These findings were consistent with those of a recent Japanese study.

The histopathological analysis classified the 44 obturator lymph nodes into 20 invasive, 18 massive, and 6 minimal metastasis types, and the 34 internal iliac lymph nodes into 16 invasive, 6 massive, and 12 minimal metastasis types. The invasive types reflected a poorer prognosis and a higher recurrence rate, as compared with the massive and minimal types. These findings suggested that the recurrence and prognosis of RC patients depend not only on the presence or absence of metastasis but also on the histopathological characteristics of the 263D and 283 lymph nodes. This may ex-
Table 2. Metastasis, 5 Year Survival Rates, and Index of the Effect of Lymph Node Dissection.

| Lymph Node Station | Metastatic numbers (%) | 5-year survival rates (%) | Value (%) |
|--------------------|-------------------------|---------------------------|-----------|
| 251-1-T            | 91 (23.9)               | 80.4                      | 19.2      |
| 251-1-O            | 91 (23.9)               | 67.5                      | 16.1      |
| 251-1-A            | 18 (4.7)                | 35.3                      | 1.6       |
| 251-2-O            | 34 (8.9)                | 51.2                      | 4.5       |
| 251-2-A            | 1 (0.3)                 | 100                       | 0.2       |
| 252                | 31 (8.1)                | 41.6                      | 3.3       |
| 253                | 6 (1.6)                 | 16.0                      | 0.3       |
| 273                | 8 (2.1)                 | 18.7                      | 0.4       |
| 263P               | 13 (3.4)                | 35.1                      | 1.2       |
| 263D               | 37 (9.7)                | 65.3                      | 6.1       |
| 283                | 44 (11.5)               | 63.9                      | 7.4       |

Table 3. Rates of Local Recurrence and Distant Metastasis in Patients with 263D and 283 Lymph Node Metastases, Assessed by the Metastasis Morphology.

| Site of recurrence | Lymph Node Classification | Number | Local | Distant | liver | lung | PL | Bone | Brain | others |
|--------------------|---------------------------|--------|-------|---------|-------|------|----|------|-------|--------|
| 263D               | A                         | 12     | 0     | 1       | 1     | 0    | 0  | 0    | 0     | 0      |
|                    | B                         | 6      | 2     | 3       | 2     | 2    | 1  | 0    | 0     | 0      |
|                    | C                         | 16     | 6     | 14      | 4     | 4    | 3  | 3    | 1     | 1      |
| 283                | A                         | 6      | 0     | 1       | 0     | 1    | 0  | 0    | 0     | 0      |
|                    | B                         | 18     | 1     | 5       | 3     | 2    | 1  | 1    | 1     | 1      |
|                    | C                         | 20     | 7     | 16      | 3     | 4    | 4  | 1    | 1     | 4      |

PL: paraaortic lymph node

Figure 4. The 5 year overall survival rates of patients with 263D and 283 lymph node metastases according to the histopathological characteristics.
plain the discrepancy between good and poor prognoses in RC patients with lateral lymph node metastasis and its dissection effect.

In Western countries, RC patients with lateral lymph node metastasis were widely used as a nonadjuvant chemotherapy. Previous studies showed the same clinical outcomes between a total mesorectal excision with lateral lymph node dissection group and a group with adjuvant radiotherapy or preoperative radiotherapy. The Dutch trail study suggested that these dysfunctional complications and postoperative mortality and morbidity were not increased after the standard lateral lymph node dissection. Kim et al. reported that the lateral lymph nodes most frequently relapse in RC patients treated with preoperative chemoradiotherapy. Taken together, the optimal therapy, which is not excessive but necessary and sufficient, is required for an individual RC patient. The present study may provide new insights on the prediction of a prognosis and the choice of an optimal postoperative treatment, including multimodality therapy for RC patients. However, the best multimodality therapy, with either perioperative or postoperative chemoradiotherapy, for RC patients remains undetermined. To address this issue, a phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower RC with suspected lateral pelvic node metastasis, JCOG1301, is underway.

In conclusion, the present retrospective study demonstrated that the recurrence and prognosis of RC patients depend not only on the presence or absence of 263D and 283 lymph node metastases but also on the histopathological characteristics. This suggests that a more precise characterization of the metastatic lateral lymph nodes is required to attain the best therapy for the individual RC patient. The present findings may contribute to appropriate judgments for treating RC patients.

Acknowledgments
The authors thank E. Ikeda, a former staff member in our division.

Compliance with ethical standards. The study protocol was approved by the institutional review board.

Conflicts of Interest
There are no conflicts of interest.

References
1. Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012 Feb; 17(1): 1-29.

2. Sugihara K, Kobayashi H, Kato T, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum. 2006 Nov; 49(11): 1663-72.

3. Ueno M, Oya M, Azekura K, et al. Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg. 2005 Jun; 92(6): 756-63.

4. Mori T, Takahashi K, Yasuno M. Radical resection with autonomic nerve preservation and lymph node dissection techniques in lower rectal cancer surgery and its results: the impact of lateral lymph node dissection. Langenbeck's Arch Surg. 1998 Dec; 383(6): 409-15.

5. Sugihara K, Moriya Y, Akasu T, et al. Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome. Cancer. 1996 Nov; 78(9): 1871-80.

6. Moriya Y, Sugihara K, Akasu T, et al. Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer. World J Surg. 1997 Sep; 21(7): 728-32.

7. Ueno H, Mochizuki H, Hashiguchi Y, et al. Prognostic determinants of patients with lateral nodal involvement by rectal cancer. Ann Surg. 2001 Aug; 234(2): 190-7.

8. Shirouzu K, Ogata Y, Araki Y, et al. Total mesorectal excision, lateral lymphadenectomy and autonomic nerve preservation for lower rectal cancer: significance in the long-term follow-up study. Kurume Med J. 2001 Dec; 48(4): 307-19.

9. Shimoyama M, Yamazaki T, Suda T, et al. Prognostic significance of lateral lymph node micrometastases in lower rectal cancer: an immunohistochemical study with CAM5.2. Dis Colon Rectum. 2003 Mar; 46(3): 333-9.

10. Kobayashi H, Mochizuki H, Kato T, et al. Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection. Dis Colon Rectum. 2009 Apr; 52(4): 567-76.

11. Ueno H, Mochizuki H, Hashiguchi Y, et al. Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann Surg. 2007 Jan; 245(1): 80-7.

12. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg. 1982 Oct; 69 (10): 613-6.

13. Fujita S, Mizusawa J, Kanemitsu Y, et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (jco/g0212); a multicenter, randomized controlled, noninferiority trial. Ann Surg. 2017 Aug; 266(2): 201-7.

14. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun; 17(6): 1471-4.

15. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001 Apr; 93(8): 583-96.

16. Akiyoshi T, Watanabe T, Miyata S, et al. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg. 2012 Jun; 255(6): 1129-34.

17. Komori K, Kanemitsu Y, Ishiguro S, et al. Analysis of lymph node metastatic pattern according to the depth of in-growth in the muscularis propria in T2 rectal cancer for lateral lymph node dissection. Dig Surg. 2011 Oct; 28(5-6): 352-9.

18. Sasako M, McCulloch P, Kinoshita T, et al. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995 Mar; 82(3): 346-51.

19. Fujita S, Akasu T, Mizusawa J, et al. Postoperative morbidity and...
mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012 Jun; 13(6): 616-21.
20. Kanemitsu Y, Komori K, Shida D, et al. Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: a comparison of 2 high-volume centers in Japan that employ different policies concerning LLND. Surgery. 2017 Aug; 162(2): 303-14.
21. Nagawa H, Muto T, Sunouchi K, et al. Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum. 2001 Sep; 44(9): 1274-80.
22. Watanabe T, Tsurita G, Muto T, et al. Extended lymphadenectomy and preoperative radiotherapy for lower rectal cancers. Surgery. 2002 Jul; 132(1): 27-33.
23. Marijnen CA, Kapiteijn E, van de Velde CJ, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2002 Feb; 20(3): 817-25.
24. Kim TH, Jeong SY, Choi DH, et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2008 Mar; 15(3): 729-37.

Journal of the Anus, Rectum and Colon is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).